SCHEMBL1107388

SCHEMBL1107388

CC(=O)[C@H](CC1CCCC1)c1ccc(S(C)(=O)=O)cc1

nearest known ligand 0.58

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
GCK P35557 14/20 0.58
KMT2A Q03164 2/20 0.43
EPHX1 P07099 1/20 0.42
MEN1 O00255 1/20 0.41
KCNH2 Q12809 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1865137 0.89 GCK (0.58) GCKKMT2AEPHX1MEN1KCNH2
SCHEMBL1865136 0.89 GCK (0.58) GCKKMT2AEPHX1MEN1KCNH2
SCHEMBL2646260 0.87 GCK (0.57) GCKKMT2AEPHX1MEN1KCNH2
SCHEMBL2650823 0.87 GCK (0.57) GCKKMT2AEPHX1MEN1KCNH2
SCHEMBL2646180 0.87 GCK (0.57) GCKKMT2AEPHX1MEN1KCNH2
SCHEMBL2667236 0.87 GCK (0.57) GCKKMT2AEPHX1KCNH2
SCHEMBL2897166 0.87 GCK (0.57) GCKKMT2AMEN1KCNH2
SCHEMBL1107300 0.86 GCK (0.56) GCKKMT2AEPHX1KCNH2
SCHEMBL13477802 0.86 GCK (0.56) GCKKMT2AEPHX1KCNH2
SCHEMBL12594351 0.86 GCK (0.45) GCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170087160-A1 USES OF DPP IV INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2017-03-30 US disclosed
US-20160000798-A1 USES OF DPP IV INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2016-01-07 US disclosed
US-9173859-B2 Uses of DPP IV inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-11-03 US disclosed
US-20140135348-A1 USES OF DPP IV INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-05-15 US disclosed
US-8673927-B2 Uses of DPP-IV inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-03-18 US disclosed
US-8232281-B2 Uses of DPP-IV inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-07-31 US disclosed
US-8153677-B2 Substituted pyrazolylamide compounds useful as glucokinase activators BRISTOL-MYERS SQUIBB COMPANY (US) 2012-04-10 US disclosed
US-8153677-B2 Substituted pyrazolylamide compounds useful as glucokinase activators BRISTOL-MYERS SQUIBB COMPANY (US) 2012-04-10 US disclosed
US-20110118211-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY 2011-05-19 US disclosed
US-20110118211-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY 2011-05-19 US disclosed
US-7910747-B2 Phosphonate and phosphinate pyrazolylamide glucokinase activators BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-22 US disclosed
US-20110065731-A1 USES OF DPP-IV INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-03-17 US disclosed
US-7888504-B2 Glucokinase activators and methods of using same BRISTOL-MYERS SQUIBB COMPANY (US) 2011-02-15 US disclosed
US-20080021052-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY 2008-01-24 US disclosed
US-20080009465-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY 2008-01-10 US disclosed
US-20080009465-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY 2008-01-10 US disclosed
WO-2008005964-A2 PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-01-10 WO disclosed
US-20070281940-A1 USES OF DPP-IV INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160000798-A1 USES OF DPP IV INHIBITORS DPP4, DPP3, DPP7 GCK 68/4885KMT2A 3365/4885EPHX1 1921/4885
US-20170087160-A1 USES OF DPP IV INHIBITORS DPP4, DPP3, DPP7 GCK 68/4885KMT2A 3365/4885EPHX1 1921/4885
US-20110118211-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME GCKR, MPO, GCK GCK 3/4885KMT2A 2216/4885EPHX1 3148/4885
US-20070281940-A1 USES OF DPP-IV INHIBITORS DPP4, DPP3, DPP7 GCK 63/4885KMT2A 3259/4885EPHX1 1958/4885
US-20110065731-A1 USES OF DPP-IV INHIBITORS DPP4, DPP3, DPP7 GCK 63/4885KMT2A 3259/4885EPHX1 1958/4885
US-20080009465-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME GCKR, GCK, PCK1 GCK 2/4885KMT2A 2344/4885EPHX1 3662/4885
US-20140135348-A1 USES OF DPP IV INHIBITORS DPP4, DPP3, DPP7 GCK 68/4885KMT2A 3365/4885EPHX1 1921/4885
US-20080021052-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME GCKR, GCK, NR4A3 GCK 2/4885KMT2A 2341/4885EPHX1 4559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.